NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results

Rhea-AI Summary

NeuroBo Pharmaceuticals (Nasdaq: NRBO) reported its financial results for the year ended December 31, 2021, revealing a net loss of $15.3 million, improving from $29.7 million in 2020. R&D expenses increased to $6.5 million, primarily due to clinical trial costs for its lead drug candidate, ANA001, targeting moderate to severe COVID-19. General and administrative expenses rose to $8.8 million. The company ended 2021 with $16.4 million in cash, projecting sufficient funds for operations into Q4 2022. Clinical progress on ANA001 is anticipated in the upcoming quarters.

Positive

• Net loss decreased to $15.3 million in 2021 from $29.7 million in 2020.
• Cash and cash equivalents increased to $16.4 million, up from $10.1 million year-over-year.
• Positive recommendation from the data safety monitoring board for the ANA001 trial.

Negative

• R&D expenses increased to $6.5 million, impacting overall financial performance.
• General and administrative expenses rose to $8.8 million, indicating rising operational costs.

BOSTON, April 1, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced financial results for the year ended December 31, 2021.

Management Commentary

"Since I joined NeuroBo in November of 2021, we have had the opportunity to significantly strengthen our team including the addition of highly accomplished executive, D. Gordon Strickland, to our Board of Directors in January and, most recently, with the appointment of Danamarie Belpulsi, M.D. to our Scientific Advisory Board. Their collective experience will be invaluable as we continue to move programs through the clinic," stated Gil Price, M.D. President and Chief Executive Officer of NeuroBo. 

"Also of note, following a positive recommendation from the independent data safety monitoring board, in the fourth quarter of last year, we continue to advance our Phase 2/3 clinical trial of lead drug candidate, ANA001, a proprietary oral niclosamide formulation, in development as a treatment for patients with moderate to severe COVID-19 and expect to complete the phase 2 portion of the trial in the third quarter of this year. We look forward to providing further updates on our clinical progress in the near future."

Management also noted that, subsequent to the October 2021 registered direct offering, the company expects that its cash will be adequate to fund operations into the fourth quarter of 2022.

Full Year 2021 Financial and Operating Results

• Research and Development (R&D) Expenses were $6.5 million for the year ended December 31, 2021 as compared to $4.5 million for the year ended December 31, 2020. The $2.0 million increase during the year ended December 31, 2021 was primarily attributed to increased clinical trial and drug manufacturing of $1.9 million and $0.4 million, respectively, for the development of ANA001, offset by a reduction of preclinical costs of $0.3 million.
   
• General and Administrative Expenses were $8.8 million for the year ended December 31, 2021 compared to $7.8 million for the year ended December 31, 2020. The increase of $1.0 million was primarily due to increased personnel costs of $0.6 million, increased costs associated with operating as a public company of $0.3 million, and increased insurance costs of $0.4 million, offset by reductions of facilities and professional fees costs of $0.3 million and $0.1 million, respectively, when compared to the comparable prior year.
   
• Net Loss for the year ended December 31, 2021 was $15.3 million, or $0.66 per basic and diluted share, based on 23,143,792 weighted average common shares outstanding, compared with a net loss of $29.7 million, or $1.83 per basic and diluted share, based on 16,217,339 weighted average common shares outstanding for the year ended December 31, 2020.
   
• Cash and Cash Equivalents were $16.4 million as of December 31, 2021, compared with $10.1 million as of December 31, 2020. Operating at its current level of clinical activity, NeuroBo expects its cash position will be adequate to fund operations into the fourth quarter of 2022.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies.

For more information visit: https://www.neurobopharma.com.

Forward Looking Statements

Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding NeuroBo's obtaining financing for development of its products and conducting clinical trials and the nature of such financing, the development of NeuroBo's product candidates, the ability to obtain regulatory and other approvals for and commence new clinical trials and the therapeutic potential, timing and nature of clinical trials and potential regulatory approval of NeuroBo's clinical programs and pipeline. Forward-looking statements are usually identified by the use of words, such as "believes," "anticipates," "expects," "intends," "plans," "may," "potential," "will," "could" and similar expressions. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. These factors, risks and uncertainties include, but are not limited to: recent changes in NeuroBo's management; the ability to obtain approval and initiate new clinical trials, including the Phase 2/3 trial as a post-exposure prophylaxis for the prevention of COVID-19; the clinical utility, potential benefits and market acceptance of NeuroBo's product candidates, including ANA001 and Gemcabene; the effect of future milestone payments and royalties on the results of operations and financial position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo's business, clinical trial sites, supply chain and manufacturing facilities; the effects of the ongoing war in Ukraine, particularly as it relates to NeuroBo's clinical trials; NeuroBo's ability to continue as a going concern; the timing of completion of NeuroBo's clinical trials, including with respect to ANA001; the timing of the availability of data from NeuroBo's clinical trials, including with respect to ANA001;  NeuroBo's ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the impact of government laws and regulations; NeuroBo's ability to protect its intellectual property position; and NeuroBo's need for additional financing and the nature of such financing to fulfill its stated goals.    Please refer to NeuroBo's most recent annual report on Form 10-K, as well as NeuroBo's subsequent filings on Form 10-Q and Form 8-K, which are available on the SEC's website (www.sec.gov), for a full discussion of the risks and other factors that may impact any forward-looking statements in this press release. In addition, the forward-looking statements included in this press release represent NeuroBo's views as of the date hereof. NeuroBo anticipates that subsequent events and developments will cause its views to change. However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof.

Contact:

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

- Tables to Follow -

 

NeuroBo Pharmaceuticals, Inc.
Consolidated Balance Sheets
(in thousands, except share amounts and par value)
		December 31,			December 31,
		2021			2020
Assets
Current assets:
Cash		$	16,387		$	10,089
Prepaid expenses			197			546
Other assets			—			48
Total current assets			16,584			10,683
Right-of-use assets and other			105			130
Property and equipment, net			110			155
Total assets		$	16,799		$	10,968
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	830		$	2,575
Accrued liabilities			1,301			1,096
Lease liability, short-term			26			24
Total current liabilities			2,157			3,695
Lease liability, long-term			45			70
Total liabilities			2,202			3,765
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of        December 31, 2021 and 2020; no shares issued or outstanding as of        December 31, 2021 and 2020.			—			—
Common stock, $0.001 par value per share, 100,000,000 shares authorized as        of December 31, 2021 and 2020; 26,661,771 and 19,671,182 shares issued        and outstanding as of December 31, 2021 and 2020, respectively.			27			20
Additional paid–in capital			96,394			73,713
Accumulated other comprehensive income			4			14
Accumulated deficit			(81,828)			(66,544)
Total stockholders' equity			14,597			7,203
Total liabilities and stockholders' equity		$	16,799		$	10,968

 

NeuroBo Pharmaceuticals, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
		For the Year Ended
		December 31,
		2021			2020
Operating expenses:
Research and development		$	6,546		$	4,531
Acquired in‑process research and development			—			17,339
General and administrative			8,752			7,846
Total operating expenses			15,298			29,716
Loss from operations			(15,298)			(29,716)
Interest income			14			39
Other expense, net			—			(1)
Loss before income taxes			(15,284)			(29,678)
Provision for income taxes			—			—
Net loss			(15,284)			(29,678)
Other comprehensive (loss) income, net of tax			(10)			2
Comprehensive loss		$	(15,294)		$	(29,676)
Loss per share:
Net loss per share, basic and diluted		$	(0.66)		$	(1.83)
Weighted average common shares outstanding:
Basic and diluted			23,143,792			16,217,339

 

View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-reports-full-year-2021-financial-results-301515393.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

What is NeuroBo Pharmaceuticals' net loss for 2021?

NeuroBo Pharmaceuticals reported a net loss of $15.3 million for the year ended December 31, 2021.

How much cash does NeuroBo Pharmaceuticals have as of December 31, 2021?

As of December 31, 2021, NeuroBo Pharmaceuticals had $16.4 million in cash and cash equivalents.

What are the key changes in expenses for NeuroBo Pharmaceuticals in 2021?

In 2021, NeuroBo's R&D expenses increased to $6.5 million, while general and administrative expenses rose to $8.8 million.

What is the status of NeuroBo's lead drug candidate, ANA001?

NeuroBo is advancing its Phase 2/3 clinical trial of ANA001, with further updates expected soon.

When does NeuroBo expect to complete the phase 2 portion of the ANA001 trial?

NeuroBo expects to complete the phase 2 portion of the ANA001 trial in the third quarter of 2022.